Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text Full Text (PDF, 4422K) PPT slides of all figures Correction Alert me when this article is cited Citation Map Services Email this article Similar articles in this journal Similar articles in PubMed Alert me to new content in the JEM Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Ferch, U. Articles by Ruland, J. PubMed PubMed Citation Articles by Ferch, U. Articles by Ruland, J. Pubmed/NCBI databases Substance via MeSH Related Collections Related Article Social Bookmarking                            What's this?

¹ Third Medical Department, Technical University of Munich, Klinikum rechts der Isar, 81675 Munich, Germany
² Department Cellular Signal Integration, ³ Laboratory of Signaling in the Immune System, Helmholtz Zentrum München—German Research Center for Environmental Health, Institute of Toxicology, 85764 Neuherberg, Germany

CORRESPONDENCE Jürgen Ruland: jruland{at}lrz.tum.de

Diffuse large B cell lymphoma (DLBCL) is the most common type of lymphoma in humans. The aggressive activated B cell–like (ABC) subtype of DLBCL is characterized by constitutive NF-B activity and requires signals from CARD11, BCL10, and the paracaspase MALT1 for survival. CARD11, BCL10, and MALT1 are scaffold proteins that normally associate upon antigen receptor ligation. Signal-induced CARD11–BCL10–MALT1 (CBM) complexes couple upstream events to IB kinase (IKK)/NF-B activation. MALT1 also possesses a recently recognized proteolytic activity that cleaves and inactivates the negative NF-B regulator A20 and BCL10 upon antigen receptor ligation. Yet, the relevance of MALT1 proteolytic activity for malignant cell growth is unknown. Here, we demonstrate preassembled CBM complexes and constitutive proteolysis of the two known MALT1 substrates in ABC-DLBCL, but not in germinal center B cell–like (GCB) DLBCL. ABC-DLBCL cell treatment with a MALT1 protease inhibitor blocks A20 and BCL10 cleavage, reduces NF-B activity, and decreases the expression of NF-B targets genes. Finally, MALT1 paracaspase inhibition results in death and growth retardation selectively in ABC-DLBCL cells. Thus, our results indicate a growth-promoting role for MALT1 paracaspase activity in ABC-DLBCL and suggest that a pharmacological MALT1 protease inhibition could be a promising approach for lymphoma treatment.

Abbreviations used: ABC, activated B cell–like; CBM, CARD11–BCL10–MALT1; DLBCL, diffuse large B cell lymphoma; GCB, germinal center B cell–like; IKK, IB kinase; PMA + Iono, PMA and ionomycin.

© 2009 Ferch et al.
This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.jem.org/misc/terms.shtml). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Article

Masking MALT1: the paracaspase's potential for cancer therapy

Domagoj Vucic and Vishva M. Dixit
J. Exp. Med. 2009 206: 2309-2312. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

• Vucic, D., Dixit, V. M. (2009). Masking MALT1: the paracaspase's potential for cancer therapy. JEM 206: 2309-2312 [Abstract] [Full Text]  

Home | Help | Feedback | Subscriptions | Archive | Search

TABLE OF CONTENTS